U.S. Pharma Stock News

Solid Power (SLDP) is in focus after reporting first quarter 2026 results alongside progress on its electrolyte commercialization plans, giving you fresh numbers and project updates to weigh against the current share price. See our latest analysis for Solid Power. Solid Power’s recent earnings update, electrolyte progress with SK On and Samsung SDI, and funding raise come after a volatile period, with a 1-day share price return of negative 12.71% and a 1-year total shareholder return of very...

Solventum Corporation recently reported Q1 2026 results showing revenue of US$2,007 million versus US$2,070 million a year earlier, with net income falling to US$13 million and GAAP EPS easing, even as adjusted EPS of US$1.48 and organic sales growth of 2.1% surpassed analyst expectations. Management reaffirmed full-year 2026 guidance, highlighted progress on a US$500 million cost-savings program and major R&D and manufacturing expansions, and began executing a US$1 billion share repurchase...

Netskope (NasdaqGS:NTSK) has introduced AgentSkope, an AI-driven agentic operations platform for automating security and network workflows. The new platform brings a suite of AI-powered agents designed to handle routine and complex operational tasks for security and network teams. This launch adds a fresh product to Netskope's portfolio in automated cybersecurity operations, an area where many enterprises are seeking more efficiency. Netskope trades at $11.4, with the stock showing a 14.5%...

Caris Life Sciences (CAI) closed FY 2025 with Q4 revenue of US$292.9 million and basic EPS of US$0.29, alongside trailing 12 month revenue of US$812.0 million and a trailing basic EPS loss of US$3.22, set against a 97% year over year revenue increase and expectations for earnings to grow about 70.5% per year with profitability projected within three years. Over recent periods, the company has seen quarterly revenue move from US$101.6 million in Q3 2024 to US$129.9 million in Q4 2024, then to...

Stryker (NYSE:SYK) has completed its acquisition of Amplitude Vascular Systems, adding new peripheral vascular technology focused on arterial disease. A law firm has launched a securities investigation into Stryker related to the March cyberattack and its reported impact on financial results. These developments come as Stryker continues recent M&A activity, following its Inari Medical deal, while also facing fresh legal and regulatory scrutiny. Stryker enters these headlines with shares at...

In early May 2026, Freshpet reported first-quarter net sales of US$297.64 million, a swing to net income of US$48.51 million and higher full-year 2026 net sales growth guidance to 8%–11%. Beyond the headline numbers, the return to profitability alongside raised sales expectations suggests that Freshpet’s operational changes and brand investments are starting to translate into financial progress. With Freshpet now profitable and lifting its 2026 sales outlook, we’ll examine how this improved...

As you might know, Primoris Services Corporation ( NYSE:PRIM ) last week released its latest first-quarter, and things...

Corcept Therapeutics reported long term survival data from its DAZALS Phase 2 trial of dazucorilant in ALS. Patients receiving 300 mg daily experienced an 87% reduction in risk of death at two years. The trial did not meet its primary functional endpoint, but the survival benefit attracted attention at the ENCALS 2025 meeting. For investors tracking NasdaqCM:CORT, this new ALS data adds another layer to the story around Corcept Therapeutics beyond its core cortisol modulation work. The...

Why Kemper Stock Is On Investors’ Radar Kemper (KMPR) has drawn attention after a stretch of weak share performance, with the stock down over the past day, week, month and past 3 months, and about 52% lower over the past year. For investors, that backdrop, alongside reported annual revenue of US$4,704.8 million and net income of US$41.9 million, raises practical questions about how to think about the company’s current valuation and risk profile. See our latest analysis for Kemper. Recent...

If you are wondering whether Micron Technology's share price still reflects fair value after a strong run, the key question is what the current market price is really paying for. The stock last closed at US$646.47, with returns of 25.0% over 7 days, 71.2% over 30 days, 105.0% year to date, and a very large 1 year gain of 661.0% that is roughly 7x. Recent headlines have focused on Micron Technology's position within the semiconductor industry and its role in supplying memory and storage for...

Diebold Nixdorf (DBD) is back on investors’ radar after VyStar Credit Union expanded its use of the company’s Branch Automation Solutions, alongside a recent first quarter update that showed revenue of US$891.8 million and net income of US$5 million. See our latest analysis for Diebold Nixdorf. The recent VyStar contract and first quarter update come after a strong run in the stock, with a 23.37% year to date share price return and a 70.17% total shareholder return over the past year,...

AI is no longer just about the mega caps at the top of every headline. With central banks reacting to inflation, oil prices swinging on Middle East tensions, and trade patterns shifting from China to Europe and beyond, smaller AI focused stocks are where early product ideas, niche data tools, and automation platforms are being built. This AI Small Caps screener is designed to filter for those under the radar opportunities that sit inside these global cross currents. In this article, you will...

Tempus AI (NasdaqGS:TEM) has completed an upsized US$400 million convertible note offering. The capital raise increases the company’s access to funding for acquisitions and investments. Shortly before the offering, Tempus AI expanded its collaboration with Quanterix/Lucent Diagnostics on Alzheimer’s disease blood tests. The Lucent Diagnostics partnership brings Tempus’ AI driven platform into neurological diagnostics alongside its existing oncology focus. For investors watching Tempus AI...

Investors may be wondering if RB Global at around US$103 a share is still offering value or if most of the upside is already priced in. The stock has been fairly steady year to date, with a 0.1% return. However, that headline number masks a 5.8% gain over the past month, a small 0.8% slip in the last week, and a return of 97.8% over three years and 85.2% over five years. Recent coverage has focused on RB Global's role in the Commercial Services sector and how investors are reacting to its...

BlackLine (NasdaqGS:BL) reported strong Q1 results, highlighting momentum across its financial automation platform. Founder Therese Tucker has retired, marking a key leadership transition for the company. Management highlighted significantly expanded adoption of BlackLine's AI-powered financial software. BlackLine focuses on software that automates and streamlines finance and accounting workflows, an area where many enterprises are still early in their digital modernization. As more...

Why Scotts Miracle-Gro is on investors’ radar Scotts Miracle-Gro (SMG) has drawn attention after its recent trading performance, with the stock showing mixed returns over the past week, month and past 3 months. This has prompted investors to reassess the lawn and garden specialist. See our latest analysis for Scotts Miracle-Gro. At a share price of $62.34, Scotts Miracle-Gro has a modest 30 day share price return of 1.43% but a weaker 90 day share price return of a 6.03% decline. Its 1 year...

Hillman Solutions Corp. recently reported first-quarter 2026 results, with sales of US$370.07 million versus US$359.34 million a year earlier, while posting a net loss of US$4.73 million and basic and diluted loss per share of US$0.02 from continuing operations. Alongside completing a US$22.51 million share repurchase program, management raised full‑year 2026 net sales guidance to a range of US$1.63 billion to US$1.73 billion, signaling increased confidence in the company’s revenue outlook...

In April 2026, Graham Corporation filed a shelf registration for up to US$56.78 million of common stock, covering 599,808 shares, providing the company with flexible access to capital. This move comes as Graham’s operations benefit from improving defense demand, a growing backlog, and higher-value programs that have supported stronger profitability and cash generation. Now we’ll explore how the new shelf registration, alongside rising analyst optimism, could influence Graham’s existing...

It's been a mediocre week for CRA International, Inc. ( NASDAQ:CRAI ) shareholders, with the stock dropping 12% to...

Some The Hanover Insurance Group, Inc. ( NYSE:THG ) shareholders may be a little concerned to see that the Independent...

The market for Knight-Swift Transportation Holdings Inc.'s ( NYSE:KNX ) shares didn't move much after it posted weak...

We didn't see Boyd Gaming Corporation's ( NYSE:BYD ) stock surge when it reported robust earnings recently. We looked...

As you might know, W.W. Grainger, Inc. ( NYSE:GWW ) just kicked off its latest first-quarter results with some very...

Arrow Electronics, Inc. ( NYSE:ARW ) defied analyst predictions to release its first-quarter results, which were ahead...